Research programme: KRAS inhibitors - Frontier Medicines
Alternative Names: Activated KRASG12CLatest Information Update: 11 Mar 2022
At a glance
- Originator Frontier Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer